Children living more than 60 miles from their surgical hospital had higher complication odds and longer stays after common procedures.
News|Articles|July 3, 2025
Q2 2025: A recap of the top headlines and interviews
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Joshua Fitch, Senior Editor
View our Q2 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.
Advertisement
Advertisement
As we move into the third quarter of 2025, Q2 brought several treatment regulatory updates and clinical trial results to help better take care of pediatric patients across the globe.
Related to this article
Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.
Julie Sweetland, PhD, shares strategies to improve vaccine conversations by explaining the science, acknowledging parental concerns, and building trust.
A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.
FDA is investigating tumor reports after Zolgensma for SMA, including 2 confirmed cases of vector integration near the GLI1 oncogene.
Jon Matthew Farber, MD, shares his thoughts on the use of noninvasive brain stimulation for ADHD.
Advertisement
Advertisement